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Introduction
In a small number of head and neck cancer patients,
‘‘explosive’’ growth of nodal metastasis occurs in the
untreated neck following removal of the primary malig-
nancy [1]. The neck—either ipsilateral and/or contralat-
eral—appears free of metastasis on routine preoperative
work-up including radiological assessment by an experi-
enced, dedicated head and neck radiologist. Within a few
weeks following surgery, nodal disease becomes overt and
surprisingly advanced in terms of volume and extracapsu-
lar spread. Although well recognized by surgeons, radio-
therapists, oncologists and pathologists, the prevalence and
incidence rates of sudden metastatic presentation are
unknown since the condition is yet to be clearly deﬁned
and explained. In the absence of residual or recurrent
disease at the primary tumor site, it seems likely that the
source of the rapidly growing nodal tumor is small
metastases or micrometastases (2 mm or less in proﬁle
diameter) [2–4] present within cervical lymph nodes, but
undetected at the time of initial surgery. An alternative
source could be tumor emboli released into the lympho-
vascular system during manipulation and surgical removal
of the primary tumor and subsequent settling in a lymph
node. This has been demonstrated in animal studies but its
role in humans is uncertain [5].
In cases where disease is already present within the
lymph node, it may be that the primary tumor was
‘‘dominant’’, preventing or suppressing growth of the nodal
deposit(s) and that the rapid growth follows loss of the
primary tumor’s inhibitory inﬂuence. Although a number
of processes may play a role in thwarting the expansion of
microscopic tumors, one critical mechanism behind tumor
dormancy is the ability of the tumor population to induce
angiogenesis [6]. It is thought that angiogenesis plays a role This paper was written by members of the International Head and
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mental evidence to suggest that removal of the primary
tumor can promote the development of nodal disease by
enhancing angiogenesis. In addition, it is possible that
depression of the immune surveillance and immune sys-
tems, related to the trauma of surgery, may allow dormant
or slow-growing nodal disease to ﬂourish. On the other
hand, while evidence for the role of psychosocial factors in
cancer initiation is limited and equivocal, evidence is
stronger for links between psychological factors such as
stress, depression, and social isolation and disease pro-
gression. Stress-related processes (such as the treatment of
the primary tumor) can impact pathways implicated in
cancer progression, including immunoregulation, angio-
genesis, and invasion. Contributions of systemic factors,
such as stress hormones, to the crosstalk between tumor
and stromal cells, appear to be critical in modulating
downstream signaling pathways with important implica-
tions for disease progression [7].
The status of isolated tumor cells (ITC) and their rela-
tionship to micrometastases remains uncertain. Staining for
the proliferation marker Ki-67 shows positive cells in 29%
of ITCs, 92% of micrometastases and 96% of macrome-
tastases [8]. However, the TNM classiﬁcation states ITCs
do not typically show evidence of proliferation or stromal
reaction (indicators of metastatic activity), or penetration
of vascular or lymphatic sinus walls, and uses size as the
deﬁning criterion (with ITCs measuring less than 0.2 mm
and micrometastases 0.2–2 mm in greatest dimension) [4].
Unlike conventional metastases, ITCs do not have a spe-
ciﬁc blood supply and rely on passive diffusion for oxygen
and nutrient supply [9, 10]. It is thought that the lack of a
speciﬁc blood supply limits the growth of the tumor
deposits and cytokinetic and apoptotic rates may be mat-
ched for long periods so that an equilibrium exists (tumor
dormancy) until they are detected and eradicated by
immune surveillance, or acquire a speciﬁc blood supply
that allows tumor growth [11]. The prevalence of dormant
tumor cells is much greater than previously thought. Both
clinical and experimental data suggest that dissemination
can occur at very early stages of tumor growth and that
disseminated cells can remain dormant rather than grow
progressively. Such asymptomatic dormancy of dissemi-
nated cells can persist for decades. However, little is
known about the mechanisms responsible for the regulation
of dormancy in these cells [6]. Several mechanisms have
been proposed to explain the onset of tumor dormancy and
the nature of the shift responsible for releasing these dor-
mant tumor cells from growth restraints. One such mech-
anism is the induction of angiogenesis. According to this
approach, the escape of tumors from dormancy depends on
the tumor population undergoing an angiogenic switch that
induces the recruitment and formation of new and
functional tumor vasculature [12]. Hypoxia and inﬂam-
matory mediators are powerful stimuli for angiogenesis
[13, 14]. Vascular endothelial growth factor (VEGF) and
the ﬁbroblast growth factor (FGF) family are two of the
more widely researched molecules in the angiogenic cas-
cade (for review, see Zimmerman et al. [13]). VEGF over-
expression in breast [15], gastrointestinal [16], and colo-
rectal [17] carcinomas is associated with the metastatic
phenotype and is predictive of a poor prognosis. Moreover,
it seems likely that angiogenic factors released in response
to wounding at the primary tumor site may enhance the
growth of micrometastases and activate dormant nodal
deposits [18–20].
In addition, it is possible that some primary tumors
produce angiostatin that inhibits angiogenesis [10]; hence,
loss of the suppressive effect following surgery on the
primary tumor removes the suppressive effect and pro-
motes metastatic growth [21–23]. The precise mechanisms
are not fully understood and it seems that some angio-
genesis inhibitors control metastatic growth by inducing
apoptosis in tumor cells [11, 24].
Although molecular and cellular components of the
‘‘angiogenic switch’’ play central roles in the transition of
non-angiogenic tumors from the dormancy stage to rapid
tumor mass expansion, many other unrelated factors can
play major roles in tumor dormancy. Tumor dormancy in
some cancers can be induced by potent immunosuppression
of tumor growth by the immune system, where equilibrium
between the immune system and the tumor cells results in
long-term persistence of tumor dormancy. There is accu-
mulating evidence that cellular as well as humoral
responses are required for immune surveillance and the
maintenance of tumor dormancy [6, 25]. The immune
system, however, appears to both prevent and promote
cancer. Indeed, various bone marrow derived cells and
inﬂammatory cells had been implicated in promoting tumor
progression and development by inducing inﬂammation
and angiogenesis [26]. The inﬂammatory process sub-
sequent to surgical resection of the primary tumor could
promote the growth of dormant micrometastases and ITCs.
Indeed, the inﬂammatory process associated with sur-
gery shares a number of central mediators and pathways
with tumor growth and invasiveness. Both cellular com-
ponents (mainly macrophages and ﬁbroblasts) and humoral
factors associated with inﬂammation have been shown to
enhance tumor growth in numerous preclinical studies.
These studies have shown that removal of the primary
cancer reactivates proliferative and metastatic pathways in
residual tumor. Relapse of disease has therefore been
related to (surgical) trauma and consequent inﬂammation
[20, 27].
However, the role of the immune system in nodal
metastasis in head and head malignancies is also poorly
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123understood. In malignant melanoma, tumor-reactive
cytotoxic T-lymphocytes are present in the tumor and the
blood [28] and spontaneous regression of the primary or
metastatic tumor is well recognized [29]. It has been
suggested that the primary melanoma might function as a
‘‘booster vaccine’’ constantly providing tumor antigens
keeping the immune system alerted [29]. Eventually, in
most patients, the tumor will escape the immune system
although this may follow a prolonged period of dor-
mancy. The phenomenon of sudden, explosive growth of
nodal metastases following removal of the primary mel-
anoma is recognized but is considered unusual and whe-
ther it is due to changes in systemic or local immunity or
angiogenesis or other as yet undeﬁned mechanisms is
uncertain [29].
As in malignant melanoma, the explosive growth of
nodal deposits following removal of the primary tumor in
head and neck cancers is unusual and contrasts sharply
with the more usual presentation of relapse in the non-
treated ipsilateral or contralateral neck when disease pre-
sents later as a slow-growing deposit often localized to a
single node [30].
Other factors have also been described in relation to
activation of dormant tumor cells. For example, in the in
vitro studies, induction of ﬁbrosis, associated with depo-
sition of type I collagen in a metastatic microenvironment,
was demonstrated to induce dormant cells to form prolif-
erative metastatic lesions through beta1-integrin signaling
[31].
Although the discussed mechanisms may explain, at
least in part, dormancy of undetected metastatic cells, the
‘‘explosive’’ speed of the growth of nodal metastasis after
removal of the primary tumor still remains an intriguing
phenomenon.
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